{{Drugbox|
|IUPAC_name = (R)-2-({1-[(5-ethyl-1,3,4-thiadiazol-2-yl)carbamoyl]cyclopentyl}methyl)valeric acid 
| image=UK-414,495_structure.png
| width=240
| CAS_number= 337962-93-3
| ATC_prefix=
| ATC_suffix= 
| ATC_supplemental=
| PubChem= 
| DrugBank=
| C = 16 | H = 25 | N = 3 | O = 3 | S = 1
| molecular_weight = 339.452 g/mol
| smiles = CCc1nnc(s1)NC(=O)C2(CC(C(O)=O)CCC)CCCC2
| bioavailability= 
| protein_bound =
| metabolism = 
| elimination_half-life= 
| excretion = 
| licence_EU = 
| pregnancy_category = 
| legal_UK = 
| routes_of_administration= 
}}

'''UK-414,495''' is a drug developed by [[Pfizer]] for the treatment of [[female sexual arousal disorder]]. UK-414,495 acts as a potent, selective inhibitor of the enzyme [[neutral endopeptidase]], which normally serves to break down the [[neuropeptide]] [[vasoactive intestinal peptide|VIP]]. The consequent increase in VIP activity alters blood flow to the genital region leading to increased lubrication and muscle relaxation.<ref name="pmid16550257">{{cite journal |author=Armer R, Warne P, Witherington J |title=Recent disclosures of clinical drug candidates |journal=Drug News & Perspectives |volume=19 |issue=1 |pages=65<U+2013>72 |year=2006 |pmid=16550257 |doi= |url=}} ISSN 0214-0934</ref><ref>{{Cite doi|10.1111/j.1476-5381.2010.00693.x}}</ref><ref>{{Cite doi|10.1111/j.1476-5381.2010.00691.x}}</ref>

==See also==
* [[ABT-670]]
* [[ABT-724]]
* [[Bremelanotide]]
* [[Cabergoline]]
* [[Flibanserin]]
* [[Intrinsa]]
* [[Melanotan II]]
* [[Pramipexole]]
* [[PF-219,061]]
* [[Tibolone]]

== References ==
{{Reflist}}

{{pharm-stub}}
